CAPIVASERTIB

Brand name:

• Truqap®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

ASTRAZENECA PTY LTD

Condition/indication:
(therapeutic use)

• Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced (unresectable) or metastatic breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (Matters arising from the minutes)

Comment:

--

Other PBAC consideration:

• CAPIVASERTIB

Submission received for:

March 2025 PBAC meeting

Opportunity for consumer comment:

Open 27/11/2024 and close 29/01/2025 (see PBS Website)

PBAC meeting:

Held on 12/03/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

23/04/2025

Lodgement of required documentation:

12/05/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/05/2025

Status:

Finalised

Government processes:

Commenced on 24/06/2025

Medicine listed on the PBS:

01/10/2025 (see PBS schedule)